CA
NZ
UK
AU
IND
US
Bio-Techne’s decision to distribute a $0.08 quarterly dividend, with payment slated for August 28, adds a modest cash component to totalShareholderreturn. The move arrives as life‑sciences ETFs have been tracking modest gains, and income‑seeking investors often weigh dividend yields alongside growth prospects. By inserting …
Bolt Biotherapeutics recorded an $8.4 million operating loss for Q2 2026, down from $9.2 million a year earlier. The narrower loss, coupled with $18.1 million in cash, gives the company a runway through Q1 2027, but sustained high R&D spend keeps investors cautious.Key HighlightsOperating …
The cash cushion and modest EPS beat together suggest the firm can press forward with its KRAS programs without immediate equity dilution.
Brookdale Senior Living's operational update reveals a significant 4.3% increase in adjusted EBITDA year-over-year, alongside a 5.5% rise in same-community revenue per available room (RevPAR). This positive development occurs despite an overall decline in total revenue, indicating that the company is strategically enhancing profitability …
Investors gain a clear efficacy signal that could translate into market‑share advantage if regulatory approval follows. The milestone also validates the company’s PLK1 inhibition strategy, reinforcing its therapeutic relevance in a high‑unmet‑need cancer segment.
Strong profit guidance from Cardinal Health has prompted analysts to lift their price targets for the healthcare provider. This upward revision reflects bullish sentiment surrounding the company after it shared news of increased profitability, despite some challenges during the quarter. The adjustment signifies a …
Organic revenue crept 0.1 %, the strongest pace since Q3 2023, while the non‑GAAP operating margin expanded 420 basis points to 20.5 %. Management highlighted a $100 million share repurchase at $174 average and a raised 2026 guidance that lifts the organic revenue outlook …
The cash decline coincided with anEarnings Per Shareof $‑0.45, falling short of the $‑0.37 consensus estimate.
The financial results coincided with a 428.8% year-to-date surge in share price, reflecting heightened investor confidence in the company’s innovative boron chemistry platform and therapeutic advancements. A recent EPS report shows a $-0.29 per share loss against a consensus estimate of $-0.23, underscoring the …
Apogee Therapeutics, Inc. (NASDAQ: APGE) secured shareholder approval for its merger with AbbVie after 46,526,253 votes represented 74.87% of the 62,140,183 shares entitled to vote at the August 11 special meeting. The outcome follows a modest quarterlyEarningsbeat and a share price hovering near its …
Please wait processing your request...